GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Question] gastric emptying — what am I missing here — 19 comments in the full submission. View in context.
153
c/glp1science·submitted 4 months ago by u/tomas_lundgren

[Question] gastric emptying — what am I missing here

Questionbranch of 7 comments

gastric emptying — what am I missing here. I would rather ask a basic question now than get this wrong quietly for two months. Started reading limitations sections first. It has changed how much weight I give to almost everything posted here. Asked a question here that I thought was stupid and got three papers back.…

Read the full submission and all 19 comments →

This branch

7 comments, started 4 months ago
u/gastric_emptying_gMOD22 points·4 months ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
[deleted]15 points·4 months ago

[deleted]

replysharereportpermalink
u/tomas_lundgrenOP11 points·4 months ago

What was the exposure in that experiment relative to therapeutic?

replysharereportpermalink
u/plain_titration12 points·4 months ago

glucagon agonism sounds paradoxical until you read the energy expenditure work

replysharereportpermalink
u/aa_analysis_andy6 points·4 months ago·edited

That conflates receptor affinity with clinical potency. They are related and they are not the same thing.

replysharereportpermalink
u/lina_ndiaye2 points·4 months ago

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

replysharereportpermalink
u/nora_lundgren12 points·4 months ago

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →